Institutional members access full text with Ovid®

Share this article on:

Encephalitis and Inherited HHV-6: Encephalitis Case Report

Cheema, Asima MD*; Katta, Joseph DO; Velez, Ana Paula MD†‡; Medveczky, Maria MS§; Medveczky, Peter G. MD§∥; Quilitz, Rod PharmD, BCOP*; Blue, Brandon J. MD; Vincent, Albert L. PhD†‡; Sandin, Ramon L. MD, MS, FCAP#**††; Greene, John N. MD, FACP*‡††

Infectious Diseases in Clinical Practice: November 2012 - Volume 20 - Issue 6 - p 419–421
doi: 10.1097/IPC.0b013e3182506ec7
Case Reports

After resolution of primary infection, human herpesvirus 6 (HHV-6) remains latent in the host and may reactivate during immunosuppression, inducing end-organ diseases. This case report describes a 56-year-old male with chronic myelomonocytic leukemia who received an allogeneic stem cell transplantation and developed chronic HHV-6 DNA in the serum. The patient was diagnosed with encephalitis. Although the patient stabilized on antiviral therapy, the viral load did not diminish. Semiquantitative polymerase chain reaction revealed that the stem cell donor cells contained germ line transmitted inherited HHV-6 (iHHV-6). Patients with iHHV-6 contain significant levels of HHV-6 DNA in the serum and cerebrospinal fluid regardless of health status due to normal cell lysis. Recently, with lymphocytes derived from iHHV-6 patients, the virus has been shown to reactivate and form new virus. Therefore, active HHV-6 infection in these cases is possible but impossible to determine from existing assays. Therefore, physicians must rely on clinical judgment to determine if the therapy would be beneficial. To complicate matters, some HHV-6 strains are resistant to foscarnet and ganciclovir. This report underscores the need for considering the diagnosis of iHHV-6 in patients harboring unusually high HHV-6 DNA levels and the need for better diagnostic tests to distinguish latent iHHV-6 from reactivated virus. The search for effective anti-HHV-6 drugs continues.

From the *Division of Infectious Diseases, H. Lee Moffitt Cancer Center and Research Institute; †Division of Infectious Diseases and International Medicine, Departments of ‡Internal Medicine, and §Molecular Medicine, University of South Florida College of Medicine; ∥Molecular Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL; ¶Washington University, St. Louis, MO; #Clinical Microbiology and Virology Laboratories, H. Lee Moffitt Cancer Center and Research Institute; Departments of **Pathology and ††Oncologic Sciences, University of South Florida College of Medicine, Tampa, FL.

Correspondence to: John N. Greene, MD, FACP, Division of Infectious Diseases, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Dr, FOB-3, Tampa, FL 33612-9497. E-mail:

The authors have no funding or conflicts of interest to disclose.

© 2012 Lippincott Williams & Wilkins, Inc.